




Edition: BP 2025 (Ph. Eur. 11.6 update)

# Rifabutin

[General Notices](#)

(Ph. Eur. monograph 1657)



C<sub>46</sub>H<sub>62</sub>N<sub>4</sub>O<sub>11</sub> 847 72559-06-9

Action and use

Rifamycin antimycobacterial drug.

Ph Eur

DEFINITION

(9*S*,12*E*,14*S*,15*R*,16*S*,17*R*,18*R*,19*R*,20*S*,21*S*,22*E*,24*Z*)-6,18,20-Trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2*H*-furo[2',3':7,8]naphtho[1,2-*d*]imidazole-2,4'-piperidine]-16-yl acetate.

Semi-synthetic product derived from a fermentation product.

Content

96.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance

Reddish-violet amorphous powder.

### Solubility

Slightly soluble in water, soluble in methanol, slightly soluble in ethanol (96 per cent).

## IDENTIFICATION

A. Infrared absorption spectrophotometry ([2.2.24](#)).

*Preparation* Discs.

*Comparison* [rifabutin CRS](#).

B. Examine the chromatograms obtained in the test for related substances.

*Results* The principal peak in the chromatogram obtained with the test solution is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (a).

## TESTS

### Impurity A

Thin-layer chromatography ([2.2.27](#)).

*Test solution* Dissolve 0.100 g of the substance to be examined in a mixture of equal volumes of [methanol R](#) and [methylene chloride R](#) and dilute to 10 mL with the same mixture of solvents.

*Reference solution* Dissolve 10 mg of [rifabutin impurity A CRS](#) in a mixture of equal volumes of [methanol R](#) and [methylene chloride R](#) and dilute to 10 mL with the same mixture of solvents. Dilute 3 mL of the solution to 100 mL with a mixture of equal volumes of [methanol R](#) and [methylene chloride R](#).

*Plate* [TLC silica gel F<sub>254</sub> plate R](#).

*Mobile phase* [acetone R](#), [light petroleum R](#) (23:77 V/V).

*Application* 10 µL.

*Development* Over 2/3 of the plate.

*Drying* In air.

*Detection* Expose the plate to iodine vapour for about 5 min, then spray with [potassium iodide and starch solution R](#) and allow to stand for 5 min.

*Limit:*

— *impurity A*: any spot corresponding to impurity A is not more intense than the spot in the chromatogram obtained with the reference solution (0.3 per cent).

### Related substances

Liquid chromatography ([2.2.29](#)).

*Test solution* Dissolve 50.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase.

*Reference solution (a)* Dissolve 50.0 mg of [rifabutin CRS](#) in the mobile phase and dilute to 50.0 mL with the mobile phase.

*Reference solution (b)* Dilute 1.0 mL of reference solution (a) to 100.0 mL with the mobile phase.

*Reference solution (c)* Dissolve about 10 mg of [rifabutin CRS](#) in 2 mL of [methanol R](#), add 1 mL of [dilute sodium hydroxide solution R](#) and allow to stand for about 4 min. Add 1 mL of [dilute hydrochloric acid R](#) and dilute to 50 mL with the mobile phase.

*Column:*

— *size*:  $l = 0.110$  m,  $\varnothing = 4.6$  mm,

— *stationary phase*: [octylsilyl silica gel for chromatography R](#) (5  $\mu$ m).

*Mobile phase* Mix equal volumes of [acetonitrile R](#) and a 13.6 g/L solution of [potassium dihydrogen phosphate R](#) adjusted to pH 6.5 with [dilute sodium hydroxide solution R](#).

*Flow rate* 1 mL/min.

*Detection* Spectrophotometer at 254 nm.

*Injection* 20  $\mu$ L.

*Run time* 2.5 times the retention time of rifabutin.

*Relative retention* With reference to rifabutin (retention time = about 9 min): impurity E = about 0.5; impurity B = about 0.6; impurity D = about 0.9; impurity C = about 1.3.

*System suitability* Reference solution (c):

— *resolution*: minimum 2.0 between the second peak of the 3 peaks due to degradation products and the peak due to rifabutin.

*Limits:*

— *any impurity*: not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent); not more than 1 such peak has an area greater than half the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent),

— *total*: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (b) (3.0 per cent),

— *disregard limit*: 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

**Water** (2.5.12)

Maximum 2.5 per cent, determined on 0.200 g.

**Sulfated ash** (2.4.14)

Maximum 0.3 per cent, determined on 1.0 g.


## ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.


*Injection* Test solution and reference solution (a).

Calculate the percentage content of rifabutin.


## IMPURITIES




A. 1-(2-methylpropyl)piperidin-4-one,




B. 3-aminorifamycin S,



C. 21,31-didehydrorifabutin,



D. 3-amino-4-imidorifamycin S,



E. 16-deacetylirifabutin.

---

Ph Eur